Cns
Oct 11, 2011 at 13:37 | Source: PTI
Sep 22, 2011 at 20:44 | Source: PTI
May 26, 2011 at 13:53 | Source: PTI
Oct 27, 2010 at 13:53 | Source: CNBC-TV18
Dec 22, 2008 at 18:50
.jpg)
News across the web »
May 29, 2012 at 20:42 | Source: Market Watch
May 29, 2012 at 19:22 | Source: Market Watch
May 29, 2012 at 18:32 | Source: Market Watch
May 29, 2012 at 10:32 | Source: Market Watch
May 29, 2012 at 07:32 | Source: Market Watch
Interact & exchange stock tips & market info »
Source:Market Watch - NEW YORK (MarketWatch) — Gold futures edged u...
about 10 hrs 9 min 1 sec ago
Source:Market Watch - HONG KONG (MarketWatch) — Gold futures edged ...
about 11 hrs 59 min 22 sec ago
Related News »
VATICAN CITY (CNS) -- Vatican spokesman Father Federico Lombardi confirmed that Paolo Gabriele, the pope's private assistant, was arrested after private Vatican documents were found in his possession in connection to the so-called "VatiLeaks" scandal that ...
May 26, 2012 at 15:41 | Source: Catholic News
Bharatbook from its exhaustive collection has come out with a report "Orphan Diseases Therapeutics in CNS to 2017" which gives an overview, Demand, Supply Trends and industry analysis report The leading business intelligence provider, has released its ...
May 18, 2012 at 06:11 | Source: PR-USA.net
In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from CNS is likely to continue, and whether the current estimated yield of 2.18% on annualized basis is a ...
May 29, 2012 at 14:19 | Source: Forbes
New Delhi, May 22 (PTI) Drug firm Suven Life Sciences today said it has received four product patents in different international markets for its new chemical entities (NCEs) which could be used in treating various central nervous system disorders.
May 22, 2012 at 11:35 | Source: MSN India
Stifel Nicolaus initiates its coverage on Supernus Pharmaceuticals (NASDAQ: SUPN) with a Buy rating and a price target of $15 per share. Stifel Nicolaus comments, "With extensive experience in product development, first as a subsidiary of Shire and then ...
May 29, 2012 at 12:38 | Source: Benzinga
The CNS pipeline is second only to cancer in terms of the number of pharmaceuticals in development. Espicom has looked at Phases I, II and III of the clinical development programme and has identified more than 270 agents. These include new chemical ...
May 16, 2012 at 15:17 | Source: Transworld News
Ono Pharmaceutical Co., Ltd. announced today that it has completed a phase II clinical study of ONO-2745/CNS 7056 (development code), which has been developed by PAION (formerly CeNeS) and now its development in Japan is promoted by ONO for general anesthesia.
May 14, 2012 at 14:01 | Source: Phramalive.com
A a decline in the dollar kept metals prices in positive territory. Gold futures for June delivery (CNS:GCM2) rose $4.90, or 0.3%, to $1,562.30 an ounce. It touched $1,566.70 an ounce during European trading hours Chinese company People's ...
May 25, 2012 at 12:14 | Source: Marketwatch
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at ...
May 15, 2012 at 10:39 | Source: FierceBiotech
According to CNS, "[t]he dioceses and organizations, in different combinations, are filing 12 different lawsuits filed in federal courts around the country." "This lawsuit is about an unprecedented attack by the federal government on one of America’s ...
May 21, 2012 at 18:24 | Source: Examiner